A review of the clinical, economic, and societal burden of treatment-resistant depression: 1996-2013

Psychiatric Services

Volumn 65, Issue 8, 2014, Pages 977-987

  Mrazek, David A ^a   Hornberger, John C ^b,c   Altar, C Anthony ^b   Degtiar, Irina ^b  

^a MAYO CLINIC   (United States)

^b Cedar Assoc LLC ^*  (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; LAMOTRIGINE; LITHIUM; OLANZAPINE; VENLAFAXINE;

ABNORMAL BLOOD PRESSURE; AGITATED DEPRESSION; ATAXIA; BLURRED VISION; BRAIN DEPTH STIMULATION; CLINICAL GLOBAL IMPRESSION SCALE; COGNITIVE THERAPY; COMORBIDITY; COST; COST EFFECTIVENESS ANALYSIS; DISEASE DURATION; DISEASE SEVERITY; DISSOCIATIVE DISORDER; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG TREATMENT FAILURE; DYSPHORIA; ERYTHEMA; EYE SWELLING; GROUP THERAPY; HAMILTON SCALE; HEALTH CARE COST; HEALTH DISPARITY; HUMAN; MAJOR DEPRESSION; MANIA; MEDLINE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NAUSEA; ORGASM DISORDER; OUTCOME ASSESSMENT; PRODUCTIVITY; PSYCHOEDUCATION; PSYCHOSEXUAL DISORDER; QUALITY OF LIFE; QUICK INVENTORY OF DEPRESSIVE SYMPTOMATOLOGY CLINICIAN RATED; REGISTER; REMISSION; REVIEW; SOCIETAL COST; SUICIDE ATTEMPT; SYSTEMATIC REVIEW; TRANSCRANIAL DIRECT CURRENT STIMULATION; TRANSCRANIAL MAGNETIC STIMULATION; TREATMENT RESISTANT DEPRESSION; TREATMENT RESPONSE; TREMOR; UNITED STATES; VAGUS NERVE STIMULATION; COST OF ILLNESS; DEPRESSIVE DISORDER, MAJOR; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; ECONOMICS; PSYCHOLOGY;

COST OF ILLNESS; DEPRESSIVE DISORDER, MAJOR; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; HUMANS; QUALITY OF LIFE;

EID: 84919445348     PISSN: 10752730     EISSN: 15579700     Source Type: Journal    
DOI: 10.1176/appi.ps.201300059     Document Type: Review

References (84)

1. Kessler RC, McGonagle KA, Zhao S, et al.: Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Archives of General Psychiatry 51:8-19, 1994.
2. Eaton WW, Martins SS, Nestadt G, et al.: The burden of mental disorders. Epidemiologic Reviews 30:1-14, 2008.
3. Kessler RC, Chiu WT, Demler O, et al.: Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Archives of General Psychiatry 62:617-627, 2005.
4. Nemeroff CB: Prevalence and management of treatment-resistant depression. Journal of Clinical Psychiatry 68(suppl 8): 17-25, 2007.
5. Greden JF: The burden of disease for treatment-resistant depression. Journal of Clinical Psychiatry 62(suppl 16):26-31, 2001.
6. The Global Burden of Disease: 2004 Update. Geneva, World Health Organization, 2004. Available at www.who.int/healthinfo/global-burden-disease/ GBD-report-2004update-full.pdf.
7. Nierenberg AA, DeCecco LM: Definitions of antidepressant treatment response, remission, nonresponse, partial response, and other relevant outcomes: a focus on treatment-resistant depression. Journal of Clinical Psychiatry 62(suppl 16):5-9, 2001.
8. Fava M, Rush AJ, Wisniewski SR, et al.: A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR.*D report. American Journal of Psychiatry 163:1161-1172, 2006.
9. Bares M, Brunovsky M, Kopecek M, et al.: Early reduction in prefrontal theta QEEG cordance value predicts response to venlafaxine treatment in patients with resistant depressive disorder. European Psychiatry 23:350-355, 2008.
10. Preskorn SH, Baker B, Kolluri S, et al.: An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl- D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder. Journal of Clinical Psychopharmacology 28:631-637, 2008.
11. Thase ME, Rush AJ: When at first you don't succeed: sequential strategies for antidepressant nonresponders. Journal of Clinical Psychiatry 58(suppl 13):23-29, 1997.
12. Barbee JG, Jamhour NJ: Lamotrigine as an augmentation agent in treatment-resistant depression. Journal of Clinical Psychiatry 63:737-741, 2002.
13. Dombrovski AY, Mulsant BH, Haskett RF, et al.: Predictors of remission after electroconvulsive therapy in unipolar major depression. Journal of Clinical Psychiatry 66:1043-1049, 2005.
14. Petersen T, Gordon JA, Kant A, et al.: Treatment resistant depression and axis I co-morbidity. Psychological Medicine 31: 1223-1229, 2001.
15. Souery D, Oswald P, Massat I, et al.: Clinical factors associated with treatment resistance in major depressive disorder: results from a European multicenter study. Journal of Clinical Psychiatry 68:1062-1070, 2007.
16. Rush AJ, Trivedi MH, Wisniewski SR, et al.: Bupropion-SR, sertraline, or venlafaxine- XR after failure of SSRIs for depression. New England Journal of Medicine 354: 1231-1242, 2006.
17. Avery DH, Isenberg KE, Sampson SM, et al.: Transcranial magnetic stimulation in the acute treatment of major depressive disorder: clinical response in an open-label extension trial. Journal of Clinical Psychiatry 69:441-451, 2008.
18. Trivedi MH, Rush AJ, Wisniewski SR, et al.: Evaluation of outcomes with citalopram for depression using measurementbased care in STAR.*D: implications for clinical practice. American Journal of Psychiatry 163:28-40, 2006.
19. McGrath PJ, Stewart JW, Fava M, et al.: Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR.*D report. American Journal of Psychiatry 163:1531-1541, 2006.
20. Cost-Effectiveness Analysis Registry. Boston, Tufts Medical Center, 2013. Available at research.tufts-nemc.org/cear4/. Accessed Aug 22, 2013.
21. Mental Disorders and Illicit Drug Use Expert Group: Methodology Part 2: Systematic Review. Sydney, Australia, University of New South Wales, 2007. Available at www.med.unsw.edu.au/gbdweb.nsf/resources/MethodologyPart2/ $file/GBD-Methodology-pt2-03Nov08.pdf.
22. Inventory of Depressive Symptomatology (IDS) and Quick Inventory of Depressive Symptomatology (QIDS). Pittsburgh, Pa, University of Pittsburgh Epidemiology Data Center, 2013. Available at www.idsqids.Org
23. Bewernick BH, Hurlemann R, Matusch A, et al.: Nucleus accumbens deep brain stimulation decreases ratings of depression and anxiety in treatment-resistant depression. Biological Psychiatry 67:110-116, 2010.
24. Clinical Global Impression (CGI). Rockville, Md, US Department of Health, Education, and Welfare, 1976.
25. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington, DC, American Psychiatric Association, 1994.
26. Hamilton M: The assessment of anxiety states by rating. British Journal of Medical Psychology 32:50-55, 1959.
27. Leucht S, Kane JM, Kissling W, et al.: Clinical implications of Brief Psychiatric Rating Scale scores. British Journal of Medical Psychology 187:366-371, 2005.
28. Dumas R, Richieri R, Guedj E, et al.: Improvement of health-related quality of life in depression after transcranial magnetic stimulation in a naturalistic trial is associated with decreased perfusion in precuneus. Health and Quality of Life Outcomes 10:87, 2012.
29. Grant MM: Beck Anxiety Inventory; in Encyclopedia of Child Behavior and Development. Edited by Goldstein S, Naglieri J. New York, Springer, 2011.
30. Kukull WA, Larson EB, Teri L, et al.: The Mini-Mental State Examination score and the clinical diagnosis of dementia. Journal of Clinical Epidemiology 47:1061-1067, 1994.
31. Papakostas GI, Petersen T, Denninger J, et al.: Somatic symptoms in treatmentresistant depression. Psychiatry Research 118:39-45, 2003.
32. Mcnair D, Lorr M, Droppleman L: EdITS Manual: Profile of Mood States. San Diego, Educational and Industrial Testing Service, 1992.
33. Feldman RL, Dunner DL, Muller JS, et al.: Medicare patient experience with vagus nerve stimulation for treatment-resistant depression. Journal of Medical Economics 16:62-74, 2013.
34. Lepine BA, Moreno RA, Campos RN, et al.: Treatment-resistant depression increases health costs and resource utilization. Revista Brasileira de Psiquiatria 34: 379-388, 2012.
35. Papakostas GI, Petersen TJ, Farabaugh AH, et al.: Psychiatric comorbidity as a predictor of clinical response to nortriptyline in treatment-resistant major depressive disorder. Journal of Clinical Psychiatry 64: 1357-1361, 2003.
36. Ivanova JI, Birnbaum HG, Kidolezi Y, et al.: Direct and indirect costs of employees with treatment-resistant and non-treatmentresistant major depressive disorder. Current Medical Research and Opinion 26:2475- 2484, 2010.
37. Malone DA, Jr, Dougherty DD, Rezai AR, et al.: Deep brain stimulation of the ventral capsule/ventral striatum for treatmentresistant depression. Biological Psychiatry 65:267-275, 2009.
38. Papakostas GI, Petersen T, Pava J, et al.: Hopelessness and suicidal ideation in outpatients with treatment-resistant depression: prevalence and impact on treatment outcome. Journal of Nervous and Mental Disease 191:444-449, 2003.
39. DiazGranados N, Ibrahim LA, Brutsche NE, et al.: Rapid resolution of suicidal ideation after a single infusion of an Nmethyl- D-aspartate antagonist in patients with treatment-resistant major depressive disorder. Journal of Clinical Psychiatry 71: 1605-1611, 2010.
40. Ferrucci R, Bortolomasi M, Vergari M, et al.: Transcranial direct current stimulation in severe, drug-resistant major depression. Journal of Affective Disorders 118:215-219, 2009.
41. Prochazka H, Sjögren M, Agren H: Oral d-fenfluramine test in treatment-refractory depression. Plasma prolactin response compared in patients with and without suicide attempts and in a healthy reference group. Journal of Affective Disorders 57: 201-208, 2000.
42. Kocsis JH, Gelenberg AJ, Rothbaum B, et al.: Chronic forms of major depression are still undertreated in the 21st century: systematic assessment of 801 patients presenting for treatment. Journal of Affective Disorders 110:55-61, 2008.
43. Bewernick BH, Kayser S, Sturm V, et al.: Long-term effects of nucleus accumbens deep brain stimulation in treatmentresistant depression: evidence for sustained efficacy. Neuropsychopharmacology 37: 1975-1985, 2012.
44. Kopell BH, Halverson J, Butson CR, et al.: Epidural cortical stimulation of the left dorsolateral prefrontal cortex for refractory major depressive disorder. Neurosurgery 69:1015-1029, 2011.
45. Schindler F, Anghelescu IG: Lithium versus lamotrigine augmentation in treatment resistant unipolar depression: a randomized, open-label study. International Clinical Psychopharmacology 22:179-182, 2007.
46. Dorée JP, Des Rosiers J, Lew V, et al.: Quetiapine augmentation of treatmentresistant depression: a comparison with lithium. Current Medical Research and Opinion 23:333-341, 2007.
47. Karp JF, Whyte EM, Lenze EJ, et al.: Rescue pharmacotherapy with duloxetine for selective serotonin reuptake inhibitor nonresponders in late-life depression: outcome and tolerability. Journal of Clinical Psychiatry 69:457-463, 2008.
48. Mahmoud RA, Pandina GJ, Turkoz I, et al.: Risperidone for treatment-refractory major depressive disorder: a randomized trial. Annals of Internal Medicine 147:593-602, 2007.
49. Seidman SN, Miyazaki M, Roose SP: Intramuscular testosterone supplementation to selective serotonin reuptake inhibitor in treatment-resistant depressed men: randomized placebo-controlled clinical trial. Journal of Clinical Psychopharmacology 25:584-588, 2005.
50. Inoue T, Tsuchiya K, Miura J, et al.: Bromocriptine treatment of tricyclic and heterocyclic antidepressant-resistant depression. Biological Psychiatry 40:151-153, 1996.
51. Shelton RC, Tollefson GD, Tohen M, et al.: A novel augmentation strategy for treating resistant major depression. American Journal of Psychiatry 158:131-134, 2001.
52. Corya SA, Williamson D, Sanger TM, et al.: A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression. Depression and Anxiety 23:364-372, 2006.
53. Lozano AM, Mayberg HS, Giacobbe P, et al.: Subcallosal cingulate gyrus deep brain stimulation for treatment-resistant depression. Biological Psychiatry 64: 461-467, 2008.
54. Taneja C, Papakostas GI, Jing Y, et al.: Cost-effectiveness of adjunctive therapy with atypical antipsychotics for acute treatment of major depressive disorder. Annals of Pharmacotherapy 46:642-649, 2012.
55. Swan J, Sorrell E, MacVicar B, et al.: "Coping with depression": an open study of the efficacy of a group psychoeducational intervention in chronic, treatment-refractory depression. Journal of Affective Disorders 82:125-129, 2004.
56. Rush AJ, Bose A, Heydorn WE: Naturalistic study of the early psychiatric use of citalopram in the United States. Depression and Anxiety 16:121-127, 2002.
57. Bauer M, Bschor T, Kunz D, et al.: Double-blind, placebo-controlled trial of the use of lithium to augment antidepressant medication in continuation treatment of unipolar major depression. American Journal of Psychiatry 157:1429-1435, 2000.
58. Lenox-Smith A, Greenstreet L, Burslem K, et al.: Cost effectiveness of venlafaxine compared with generic fluoxetine or generic amitriptyline in major depressive disorder in the UK. Clinical Drug Investigation 29:173-184, 2009.
59. Revicki DA, Wood M: Patient-assigned health state utilities for depression-related outcomes: differences by depression severity and antidepressant medications. Journal of Affective Disorders 48:25-36, 1998.
60. Aziz M, Mehringer AM, Mozurkewich E, et al.: Cost-utility of 2 maintenance treatments for older adults with depression who responded to a course of electroconvulsive therapy: results from a decision analytic model. Canadian Journal of Psychiatry 50: 389-397, 2005.
61. Benedict A, Arellano J, De Cock E, et al.: Economic evaluation of duloxetine versus serotonin selective reuptake inhibitors and venlafaxine XR in treating major depressive disorder in Scotland. Journal of Affective Disorders 120:94- 104, 2010.
62. Nuijten MJ: Assessment of clinical guidelines for continuation treatment in major depression. Value in Health 4:281-294, 2001.
63. Sava FA, Yates BT, Lupu V, et al.: Costeffectiveness and cost-utility of cognitive therapy, rational emotive behavioral therapy, and fluoxetine (Prozac) in treating depression: a randomized clinical trial. Journal of Clinical Psychology 65:36-52, 2009.
64. Corey-Lisle PK, Birnbaum HG, Greenberg PE, et al.: Identification of a claims data "signature" and economic consequences for treatment-resistant depression. Journal of Clinical Psychiatry 63: 717-726, 2002.
65. Olchanski N, McInnis Myers M, Halseth M, et al.: The economic burden of treatmentresistant depression. Clinical Therapeutics 35:512-522, 2013.
66. Cancer Facts and Figures 2011. Atlanta, Ga, American Cancer Society, 2011.
67. American Diabetes Association: Economic costs of diabetes in the US in 2007. Diabetes Care 31:596-615, 2008.
68. Gillum LA, Gouveia C, Dorsey ER, et al.: NIH disease funding levels and burden of disease. PLoS ONE 6:e16837, 2011.
69. Pukrop R, Schlaak V, Möller-Leimkühler AM, et al.: Reliability and validity of quality of life assessed by the Short-Form 36 and the Modular System for Quality of Life in patients with schizophrenia and patients with depression. Psychiatry Research 119: 63-79, 2003.
70. Birmaher B, Ryan ND, Williamson DE, et al.: Childhood and adolescent depression: a review of the past 10 years: part I. Journal of the American Academy of Child and Adolescent Psychiatry 35:1427-1439, 1996.
71. Vanheusden K, Mulder CL, van der Ende J, et al.: Young adults face major barriers to seeking help from mental health services. Patient Education and Counseling 73: 97-104, 2008.
72. Fleury MJ, Grenier G, Bamvita JM, et al.: Comprehensive determinants of health service utilisation for mental health reasons in a Canadian catchment area. International Journal for Equity in Health 11: 20, 2012.
73. Brent DA, Emslie GJ, Clarke GN, et al.: Predictors of spontaneous and systematically assessed suicidal adverse events in the treatment of SSRI-resistant depression in adolescents (TORDIA) study. American Journal of Psychiatry 166: 418-426, 2009.
74. Wilke RA, Dolan ME: Genetics and variable drug response. JAMA 306:306-307, 2011.
75. Winner J, Allen JD, Altar CA, et al.: Psychiatric pharmacogenomics predicts health resource utilization of outpatients with anxiety and depression. Translational Psychiatry 3:e242, 2013.
76. Hall-Flavin DK, Winner JG, Allen JD, et al.: Using a pharmacogenomic algorithm to guide the treatment of depression. Translational Psychiatry 2:e172, 2012.
77. Hall-Flavin DK, Winner JG, Allen JD, et al.: Utility of integrated pharmacogenomic testing to support the treatment of major depressive disorder in a psychiatric outpatient setting. Pharmacogenetics and Genomics 23:535-548, 2013.
78. Altar CA, Hornberger J, Shewade A, et al.: Clinical validity of cytochrome P450 metabolism and serotonin gene variants in psychiatric pharmacotherapy. International Review of Psychiatry 25:509-533, 2013.
79. Mrazek DA, Lerman C: Facilitating clinical implementation of pharmacogenomics. JAMA 306:304-305, 2011.
80. Simon GE, Perlis RH: Personalized medicine for depression: can we match patients with treatments? American Journal of Psychiatry 167:1445-1455, 2010.
81. Alegría M, Chatterji P, Wells K, et al.: Disparity in depression treatment among racial and ethnic minority populations in the United States. Psychiatric Services 59: 1264-1272, 2008.
82. Berry JG, Bloom S, Foley S, et al.: Health inequity in children and youth with chronic health conditions. Pediatrics 126(suppl 3): S111-S119, 2010.
83. Williams DR, Gonzàlez HM, Neighbors H, et al.: Prevalence and distribution of major depressive disorder in African Americans, Caribbean blacks, and non-Hispanic whites: results from the National Survey of American Life. Archives of General Psychiatry 64: 305-315, 2007.
84. Surault P: Mental health and social determinants [in French]. L'Encéphale 36(suppl): 27-32, 2010.